Pharmaceuticals
Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
SHANGHAI, July 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA). 7MW3711...
2023-07-22 00:00
4433
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * If approved by the European Commission, ORSERDU would be the first an...
2023-07-21 23:44
5722
SunHo Announces First Patient Dosed in Phase I/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979
NANJING, China, July 21, 2023 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IBB0979 (B7H3-IL10 immunocytokine), a potential first...
2023-07-21 22:51
2962
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent
* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America * "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023...
2023-07-21 16:47
2014
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference
BEIJING and SHANGHAI and BOSTON, July 20, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 Europ...
2023-07-21 10:19
1901
Saphnelo now available in Malaysia as an add-on treatment for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)
KUALA LUMPUR, Malaysia, July 21, 2023 /PRNewswire/ -- AstraZeneca's Saphnelo ( anifrolumab) has now become available as add-on treatment for adult patients in Malaysia with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE) following insufficient response to sta...
2023-07-21 10:00
2368
US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer
SEONGNAM, South Korea, July 20, 2023 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced onJuly 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development. SNB-101 is the world...
2023-07-21 08:15
1920
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study
HANGZHOU, China, July 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with atopic dermatitis in a Phase Ib clinical trial of its innovative drug LNK0100...
2023-07-21 08:00
2942
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
WATERTOWN, Mass., July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research a...
2023-07-20 19:15
2409
BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial
WUXI, China, July 19, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the dosing of the first patient in a Phase 1a/1b...
2023-07-20 10:41
1975
Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech
ZHUHAI, China, July 19, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, announced today that it has entered into a strategic research collaboration, option and worldwi...
2023-07-20 09:01
1958
Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SHANGHAI, July 20, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98 patients with ...
2023-07-20 08:10
2617
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated[...
2023-07-19 16:14
2486
The International Conference on Pharmaceutical Innovation and Development 2023 Kicked off in Yantai
YANTAI, China, July 19, 2023 /PRNewswire/ -- On the morning of July 13, the International Conference on Pharmaceutical Innovation and Development 2023 kicked off in Yantai. The conference was hosted by the People's Government of Shandong Province, co-sponsored by the Chinese Pharmaceutical Associa...
2023-07-19 16:09
2240
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication
SHANGHAI , July 18, 2023 /PRNewswire/ -- The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma ofthe United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) ("this new ind...
2023-07-19 10:42
1797
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet
SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...
2023-07-19 08:52
2309
First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib
MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstad...
2023-07-19 05:00
2286
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
SHANGHAI, July 18, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA). 9MW2921 is dev...
2023-07-19 00:00
2765
Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility
INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual report outlines the company's progress toward its sustain...
2023-07-18 19:00
1860
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
* DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics * Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients * Acquisitio...
2023-07-18 15:00
5016
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 278 media titles]
2024-11-25 10:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9306
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
9289
